Search

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz explores the cultural phenomenon surrounding GLP-1 drugs, highlighting how their emergence coincides with our wellness-obsessed, algorithm-driven age, which fosters a biohacking culture and influences widespread interest in these medications for weight loss and improved focus. #HealthInnovation #Pharmaceuticals #WellnessCulture #CN

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz explores the cultural phenomenon and scientific basis behind GLP-1 drugs, highlighting how they mimic a state of food poisoning to suppress appetite and induce nausea, raising questions about their appeal beyond just their therapeutic effects. #Health #Pharmaceuticals #Nutrition #Nocountriesmentioned.

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz explores how the popularity of GLP-1 drugs, like Wegovy and retatrutide, is influenced not only by their effectiveness in weight loss but also by the cultural obsession with wellness and social media that promotes biohacking and easy access to such substances. #HealthInnovation #Pharmaceuticals #WellnessCulture #CN

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz explores how the rise of GLP-1 drugs, such as Wegovy and retatrutide, reflects not only their efficacy as weight loss solutions but also the impact of social media and a wellness-obsessed culture, leading to a surge in online interest and experimentation with these substances amidst concerns about safety and purity. #Health #Wellness #Pharmaceuticals #CN

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz explores how GLP-1 medications, like Wegovy, have become a cultural phenomenon intersecting with our wellness-obsessed, algorithm-driven age, highlighting the implications of their rise amid social media, biohacking, and the increasing ease of accessing unregulated substances online. #Health #Wellness #Pharmaceuticals #CN

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz explores how the popularity of GLP-1 drugs, like Wegovy, intersects with today's wellness-focused, algorithm-driven culture, highlighting the surge in biohacking and the risks associated with ordering unregulated peptides online. #Health #Wellness #Pharmaceuticals #CN

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz analyzes the rise of GLP-1 drugs like Wegovy and retatrutide, exploring how their popularity is fueled not just by their weight-loss effects but by the influence of social media culture and a wellness-obsessed society that encourages biohacking and unregulated drug use. #Health #Wellness #Pharmaceuticals #CN

U.S. Health Secretary Robert F. Kennedy Jr. is proposing initiatives to reduce the use of widely prescribed selective serotonin reuptake inhibitors (SSRIs) despite the department denying discussions about banning them, amidst ongoing debates about their overprescription and links to withdrawal challenges and violence, while emphasizing the need for better research and support for patients. #MentalHealth #Pharmaceuticals #Antidepressants #US

The California Supreme Court will review a case involving Gilead Sciences, which is appealing lower court decisions allowing HIV patients to pursue negligence claims over the company's halt in developing a potentially safer alternative drug, a ruling that could reshape product liability law and impose a "duty to innovate" on drug manufacturers. #Pharmaceuticals #Innovation #ProductLiability #US

The California Supreme Court is set to review whether drug manufacturers, such as Gilead Sciences, are legally required to continue developing allegedly safer alternatives to their existing drugs, following a negligence claim from approximately 24,000 HIV patients regarding Gilead's decision to cease development of a new drug with fewer side effects. #Pharmaceuticals #ProductLiability #Innovation #US

Biontech plant die Schließung mehrerer Produktionsstandorte aufgrund von Überkapazitäten und Kosteneinsparungen, was voraussichtlich bis zu 1.860 Arbeitsplätze kosten könnte, während das Unternehmen seine Ressourcen auf die Entwicklung von Krebsmedikamenten konzentriert. #BioNTech #mRNA #Pharmaceuticals

Anti-obesity ads: Pharmaceutical companies Novo Nordisk and Eli Lilly fined 2 million euros by the drug agency. (Original: Publicités anti-obésité: Les laboratoires pharmaceutiques Novo Nordisk et Eli Lilly sanctionnés de 2 millions d'euros par l'agence du médicament https://t.co/6qi067hLi8) #AntiObesity #Pharmaceuticals #HealthRegulation #DN #FI #NL

The Brazilian Health Regulatory Agency (Anvisa) has issued a total suspension of medications containing clobutinol due to significant health risks, including the potential for severe cardiac arrhythmias, requiring the immediate withdrawal of these products from the market and advising patients to seek alternative treatments. #HealthSafety #Pharmaceuticals #Regulation

The EU Health Forum in Zagreb highlighted the potential consequences of the new EU directive on wastewater purification, which poses a financial burden on pharmaceutical manufacturers and raises concerns about the ability to simultaneously protect the environment and ensure access to essential medications, especially in smaller markets like Croatia. #EUDirective #Pharmaceuticals #EnvironmentalProtection #HR #EU #NL

Roche CEO Thomas Schinecker warned that Europe risks falling behind the U.S. and China in pharmaceutical research due to excessive bureaucracy and government policies that threaten jobs, emphasizing the need for rational regulations and urging wealthier countries to fairly compensate for innovation to sustain drug development while maintaining access to medicines in less affluent markets. #Pharmaceuticals #Innovation #Healthcare #DE #GB #FR #IT #US #CN

Roche CEO Thomas Schinecker warned that Europe may fall further behind the U.S. and China in pharmaceutical innovation due to excessive bureaucracy and government policies, exacerbated by President Trump's pricing initiatives, which have already led to a significant decrease in new drug launches in Europe. #Pharmaceuticals #Innovation #Healthcare